August 13th 2025
Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for AYA patients.
August 6th 2025
The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.
May 8th 2025
Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.
April 28th 2025
AYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.
April 25th 2025
Findings from the phase 1 BrainChild-03 trial support breakthrough designation for BCB-276 for pediatric diffuse intrinsic pontine glioma.
Targeted Interventions for Physical Activity Aids Long-Term Effects in AYAs With Cancer
Findings highlighted that increased physical activity was associated with a variety of benefits in improving overall well-being in early adolescent and young adult survivors.
Intro to AYA Patients, Survivors, and Substance Use
Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited support, and coping mechanisms, necessitating targeted prevention.
Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS Tumors
Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.
Mirdametinib Boosts Outcomes, QOL in NF1-PN
Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma
The FDA granted elraglusib a rare pediatric disease designation for Ewing sarcoma based on findings from the 1/2 Actuate-1902 trial.
Oncology Drugs Approved by the FDA in June 2024
Throughout June, the FDA approved drugs for the treatment of diseases including myelodysplastic syndrome, thyroid cancer, endometrial cancer, colorectal cancer, and follicular lymphoma.
FDA OKs Blinatumomab for Children, Adults with CD-19 B-ALL in Consolidation Phase
The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.
FDA Approves Selpercatinib for Pediatric Patients With RET-Altered Metastatic Thyroid Cancer, Solid Tumors
Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.
Oncology Drugs That Received FDA Approval in April 2024
Throughout April, the FDA approved drugs for the treatment of diseases including solid tumors, lung cancer, multiple myeloma, bladder cancer, and low-grade glioma.
Tovorafenib Gets Accelerated Approval for Pediatric Low-Grade Glioma
The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.
FDA Approves First Radioactive Drug for Children With SSTR-Positive GEP-NETs
Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
LSTA1 Receives Rare Pediatric Disease Designation From FDA for Osteosarcoma
The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.
NCCN Releases Treatment Recommendations for Neuroblastoma
The NCCN has published its first set of treatment recommendations patients with for neuroblastoma.
Creative Art Therapy Lessens Anxiety in Pediatric Patients With Cancer
Oncology nurses can bring creative art to their pediatric patients with cancer, thereby potentially reducing their anxiety levels, research showed.
Most AYA Cancer Survivors Do Not Properly Understand Their Fertility Risks
Proper counseling is needed to help decrease fertility-related psychological distress in adolescent/young adult cancer survivors.
Entrectinib Is Approved for Pediatric Patients with NTRK+ Solid Tumors
The FDA has approved entrectinib to treat pediatric patients ages 1 month and older with NTRK-positive solid tumors.
Bosutinib Is Approved for Pediatric Ph+ CP–Chronic Myeloid Leukemia
The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.
FDA Delivers Complete Response Letter to Remestemcel-L in Pediatric Steroid-Refractory aGVHD
The resubmitted biologics license application for remestemcel-L has been issued a complete response letter.
Complex Cancer Cases: Veno-Occlusive Disease in a Pediatric Patient Receiving Nontransplant-Associated Chemotherapy
Veno-occlusive disease or sinusoidal obstruction syndrome is commonly associated as a complication with transplant in pediatric patients but can also be seen with chemotherapy alone.
Blinatumomab Receives Full Approval for MRD-Positive B-Cell ALL
The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.
Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.
New Research Pinpoints Potential Risk Factors for Late Deaths in Childhood Cancer Survivors
A cohort study identified factors associated with late deaths in childhood cancer survivors.
Educational Interventions Prove Beneficial for Caregivers of Pediatric Patients Receiving HSCT
Nurse researchers sought to improve the communication between the hematopoietic stem cell transplantation care team and pediatric patient caregivers.
NCCN Guidelines Support Sodium Thiosulfate to Mitigate Cisplatin-Induced Hearing Loss in Pediatric Patients With Cancer
According to Fennec Pharmaceuticals, the National Comprehensive Cancer Network is updating it guidelines to recommend injections of sodium thiosulfate to reduce the risk of ototoxicity in pediatric patients receiving cisplatin.
Challenges Faced by Adolescent and Young Adult Patients With Cancer
Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.
Enteral Nutrition Pathway for Pediatric Patients Highlights Challenges in Combatting Malnutrition During HSCT
Nurse investigators created an enteral nutrition standardized pathway for pediatric patients about undergoing hematopoietic stem cell transplantation.
Intensified CNS-Directed Therapy Worsens Neurocognitive Function in Pediatric Patients With Acute Lymphoblastic Leukemia
Patients who receive high cumulative doses of triple intrathecal therapy may be at an increased risk of neurocognitive problems.
Cepero Defines the Importance of a Holistic Approach to Pediatric Oncology Care
Jesus Cepero, PhD, RN, highlights the value of holistic care environments in pediatric oncology.
Managing CRS in Hematologic Cancers: A Nursing Perspective
Safer Care in Breast Cancer: Expert Advice for Managing ADC Toxicities
How Nurses Can Assess and Manage Talquetamab Toxicities
Transformative Care: A Nurse Guide to Novel Therapies in Blood Cancers